This therapeutic deficit is particularly relevant to the clinical manifestations of triple-negative breast cancers (TNBCs), which lack expression of hormone receptors (estrogen receptor-α and progesterone receptor), and of the ErbB2/HER2 amplicon. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.